Prof. Jun Xue 薛军
Chief Physician, Professor
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive and individualized treatment of primary and metastatic liver cancer, including radiotherapy for portal vein tumor thrombus. Management of abdominal tumors such as gastric, colorectal, biliary, and pancreatic cancers. Palliative care for advanced-stage malignancies.
Dr. Xue is a Professor, Chief Physician, and doctoral supervisor at Union Hospital. Holding a medical degree and having studied in the United States, Dr. Xue completed one year of radiotherapy research at Fox Chase Cancer Center from 2011 to 2012. With over ten years of clinical and research experience, Dr. Xue specializes in precise radiotherapy and the early diagnosis and comprehensive treatment of gastrointestinal and liver cancers.
Professional roles
- Member, Liver Cancer Committee, Chinese Society of Clinical Oncology (CSCO)
- Member, Liver Cancer Committee, China Anti-Cancer Association (CACA)
- Vice Chair, Precision Radiotherapy Committee, Hubei Clinical Oncology Society
- Standing Committee Member, Digestive System Tumor Expert Committee, Precision Radiotherapy Branch, Chinese Society of Biomedical Engineering
Name order: in Chinese the family name comes first (Xue Jun). Papers usually list the name as Jun Xue or Xue J.
Selected publications
44 papers on PubMed matched by name and affiliation; 17 as first or senior author since 2016. Most recent first- or senior-author papers:
- Adv Radiat Oncol, 2026 (senior author): Neoadjuvant Early Stereotactic Body Radiation Therapy Followed by Chemoimmunotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer. PubMed 42571456
- Cancer Pathog Ther, 2026 (senior author): Safety and efficacy of JWATM204, a novel Glypican-3 (GPC3)-targeted CAR T cell therapy for advanced hepatocellular carcinoma: A phase I dose-escalation study. PubMed 41859477
- Sci China Life Sci, 2026 (senior author): Repositioning ACLY in liver cancer: from metabolic enzyme to a regulator of antitumor immunity. PubMed 41604103
- Curr Med Sci, 2026 (senior author): Cadonilimab Plus Lenvatinib Combined with Stereotactic Body Radiotherapy for Conversion Therapy in Unresectable or Potentially Resectable Hepatocellular Carcinoma: A Study Protocol. PubMed 41954707
- Nat Commun, 2025 (senior author): Stereotactic body radiotherapy with sintilimab and bevacizumab biosimilar in anti-PD-1 refractory hepatocellular carcinoma: the ReUNION-1 phase 2 trial. PubMed 41413036
- Adv Sci (Weinh), 2024 (first author): Deciphering the Multifaceted Immune Landscape of Unresectable Primary Liver Cancer to Predict Immunotherapy Response. PubMed 39467150
- BMJ Open, 2024 (senior author): Efficacy and safety of SBRT combined with sintilimab and IBI305 in patients with advanced HCC and previously failed immunotherapy: study protocol of a phase 2 clinical trial. PubMed 38858156
- Clin Cancer Res, 2023 (senior author): Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. PubMed 37556120
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers; we checked the papers' affiliations and topics against this doctor's department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion